XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 60 filers reported holding XENON PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $9,583,178 | -11.3% | 280,538 | 0.0% | 2.98% | +0.9% |
Q2 2023 | $10,800,713 | -4.5% | 280,538 | -11.2% | 2.95% | -12.9% |
Q1 2023 | $11,312,933 | -9.2% | 316,092 | 0.0% | 3.39% | -3.4% |
Q4 2022 | $12,463,508 | -8.0% | 316,092 | -15.8% | 3.51% | -3.7% |
Q3 2022 | $13,546,000 | +1.5% | 375,223 | -14.5% | 3.64% | +0.2% |
Q2 2022 | $13,343,000 | +14.8% | 438,623 | +15.4% | 3.64% | +20.1% |
Q1 2022 | $11,622,000 | -7.6% | 380,163 | -5.6% | 3.03% | -4.3% |
Q4 2021 | $12,579,000 | +102.5% | 402,667 | -1.0% | 3.16% | +91.9% |
Q3 2021 | $6,212,000 | -17.9% | 406,535 | 0.0% | 1.65% | +4.1% |
Q2 2021 | $7,570,000 | +4.0% | 406,535 | 0.0% | 1.58% | -8.3% |
Q1 2021 | $7,277,000 | +36.5% | 406,535 | +17.3% | 1.73% | +8.9% |
Q4 2020 | $5,330,000 | +38.9% | 346,535 | 0.0% | 1.59% | +27.2% |
Q3 2020 | $3,836,000 | -11.7% | 346,535 | 0.0% | 1.25% | -0.6% |
Q2 2020 | $4,346,000 | +10.6% | 346,535 | 0.0% | 1.25% | -23.5% |
Q1 2020 | $3,930,000 | +20.5% | 346,535 | +39.3% | 1.64% | +46.4% |
Q4 2019 | $3,262,000 | +9.5% | 248,854 | -24.7% | 1.12% | 0.0% |
Q3 2019 | $2,979,000 | -8.6% | 330,667 | 0.0% | 1.12% | -8.6% |
Q2 2019 | $3,260,000 | -3.0% | 330,667 | 0.0% | 1.22% | -15.5% |
Q1 2019 | $3,360,000 | +124.0% | 330,667 | +39.1% | 1.45% | +94.4% |
Q4 2018 | $1,500,000 | -52.2% | 237,683 | 0.0% | 0.75% | -42.1% |
Q3 2018 | $3,137,000 | +15.8% | 237,683 | -19.3% | 1.29% | +1.6% |
Q2 2018 | $2,708,000 | +46.3% | 294,362 | -22.1% | 1.27% | +40.9% |
Q1 2018 | $1,851,000 | +73.5% | 377,695 | 0.0% | 0.90% | +56.5% |
Q4 2017 | $1,067,000 | -4.2% | 377,695 | 0.0% | 0.58% | -16.9% |
Q3 2017 | $1,114,000 | -6.4% | 377,695 | 0.0% | 0.69% | -18.5% |
Q2 2017 | $1,190,000 | -12.4% | 377,695 | +11.2% | 0.85% | -26.1% |
Q1 2017 | $1,358,000 | -65.7% | 339,614 | -33.9% | 1.15% | -67.0% |
Q4 2016 | $3,959,000 | -4.9% | 514,091 | 0.0% | 3.48% | +19.9% |
Q3 2016 | $4,164,000 | +229.7% | 514,091 | +140.1% | 2.90% | +189.7% |
Q2 2016 | $1,263,000 | -6.4% | 214,091 | +10.8% | 1.00% | -14.1% |
Q1 2016 | $1,350,000 | +71.8% | 193,195 | +97.7% | 1.16% | +66.2% |
Q4 2015 | $786,000 | +279.7% | 97,730 | +290.9% | 0.70% | +242.0% |
Q3 2015 | $207,000 | – | 25,000 | – | 0.20% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 266,961 | $9,119,388 | 10.70% |
COMMODORE CAPITAL LP | 1,845,000 | $63,025,200 | 7.37% |
TLS Advisors LLC | 32,956 | $1,126 | 4.56% |
Altium Capital Management LP | 228,000 | $7,788,480 | 4.06% |
Paradigm Biocapital Advisors LP | 1,491,835 | $50,961,084 | 3.46% |
GREAT POINT PARTNERS LLC | 500,001 | $17,080,034 | 3.11% |
DAFNA Capital Management LLC | 280,538 | $9,583,178 | 2.98% |
Nan Fung Group Holdings Ltd | 106,680 | $3,644,189 | 2.95% |
Affinity Asset Advisors, LLC | 300,438 | $10,262,962 | 2.89% |
Avoro Capital Advisors LLC | 4,900,000 | $167,384,000 | 2.61% |